InPen™ is a prescription-only device. Access programs are available for those with commercial insurance. Each InPen™ is reusable for one year. Terms and conditions apply.
Smart insulin products
InPen™ smart insulin pen
Smart insulin products
InPen™ smart insulin pen
InPen™ is a smart insulin pen that connects to a mobile app to provide dosing calculations, reminders, and CGM system integration for diabetes patients.
Description
The InPen™ smart insulin pen empowers you and your patients with actionable data not available through multiple daily injections (MDI), until now.
Features
Intuitive decision support
InPen™ helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support.
Humalog® is a registered trademark of Eli Lilly and Company.
Fiasp® and Novolog® are registered trademarks of Novo Nordisk A/S
InPen™ helps solve common MDI challenges
Missing 2 doses per week can lead to an increase in A1C of up to 0.4%1
2 out of 3 people need help calculating their doses and 60% of doses are stacked2–4
Lack of accurate dosing data is a barrier to optimizing glycemic control5
The use of a bolus calculator is associated with a 0.7–1.0% reduction in A1C6–8
Patient data in one convenient place
Integrated, reliable diabetes data
InPen™ Insights Reports provide a way to view a patient’s glucose, carbohydrate, and insulin dosing data from their InPen system.
Easy collaboration
InPen™ Insights Reports help providers assess a patient’s insulin doses and glycemic levels, regardless of which multiple daily injection regimen the patient is following.
Example patient profile
InPen access programs are available to those with commercial insurance.
Terms and conditions apply.
A system that helps make life easier for your patients
InPen helps MDI users take the right amount of insulin at the right time, thanks to real-time tracking and decision support
- Tracks active insulin
- Reminds user to dose
- Calculates personalized doses
- Automatically logs doses
- Syncs with CGMs and glucose meters
Starting April 25, 2025, Medtronic will be discontinuing the sales of the Guardian™ Connect system, including the sensor and transmitter. The mobile app will no longer be available after October 24, 2025.
Frequently asked questions
* Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration.
1. Randlov, J., Poulsen, J.U. J Diabetes Sci Technol. 2008 Mar; 2(2): 229-235. Published online 2008 Mar. doi: [10.1177/1932296 80800200209]
2. Garg SK, Bookout TR, McFann KK, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technology and Therapeutics. 2008; 10(5):369-375.
3. Zaugg, Stephanie D., et al. “Diabetes numeracy and blood glucose control: association with type of diabetes and source of care.” Clinical diabetes: a publication of the American Diabetes Association 32.4 (2014): 152-157.
4. Cavanaugh, Kerri, et al. “Association of numeracy and diabetes control.” Annals of Internal Medicine. 148.10 (2008): 737-746.
5. Klonoff DC, Kerr D. Smart Pens Will Improve Insulin Therapy. J Dia Sci & Tech. 2018;12(3):551-553.
6. Ziegler R, Cavan DA, Cranston I, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013; 36(11):3613-3619.
7. Kaufman FR, Halvorson M, Carpenter S. Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care. 1999; 22(8):1252-1257.
8 Anderson DG. Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII. Pediatric Diabetes. 2009; 10(5):304-309.